Last $128.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
AKBLF On Other Exchanges
As of 4:30 PM 01/27/14 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Key Developments

ALK-Abelló A/S Presents at 7th Kempen & Co Healthcare/Life Sciences Conference, Apr-01-2014

ALK-Abelló A/S Presents at 7th Kempen & Co Healthcare/Life Sciences Conference, Apr-01-2014 . Venue: Amsterdam, Netherlands.

ALK-Abelló A/S Revises Earnings Guidance for the Year 2014

ALK-Abelló A/S revises earnings guidance for the year 2014. The company announced that the milestone payment will be booked as revenue from SLIT-Tablets in North America and the company now expects operating profit (EBITDA) to be DKK 300-400 million before special items, income from product supply, and potential sales royalties in North America against previously provided guidance of DKK 225-400 million. The higher end of this range assumes two additional product development milestone payments from Merck.

Alk-Abelló A/S Approves Ordinary Dividend

ALK-Abelló A/S approved ordinary dividend of DKK 5.00 per share at the annual general meeting held on 12 March 2014.

Alk and Torii Announce Positive Phase II/III Results from Japan Trial of Anti-Allergen

Torii Pharmaceutical and its Danish development partner ALK Abello have announced positive results from a Phase II/III clinical study of investigational drug TO-203. The drug candidate is a sublingual tablet investigated as an allergen immunotherapy for house dust mite allergy in patients with allergic rhinitis. The companies said TO-203 has met the primary endpoint of providing statistically significant improvement in total combined rhinitis score (TCRS) compared to placebo, in patients with house dust mite-induced allergic rhinitis.

ALK-Abelló A/S Proposes Amendments to Articles of Association

ALK-Abelló A/S announced that at the Annual General Meeting to be held on March 12, 2014, the Board of Directors will propose that the Chairman and the Vice Chairman of the Board shall in future be elected by the general meeting rather than by the present procedure, whereby the Board selects its own Chairman and Vice Chairman. This proposal means that article 8.1 of the Articles of Association will be amended.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $128.00 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 19.25 GBp -0.50
DBV Technologies SA €15.72 EUR +0.38
Merck & Co Inc $56.47 USD +0.21
Sanofi €75.48 EUR +0.71
Stallergenes SA €57.57 EUR -0.43
View Industry Companies

Industry Analysis


Industry Average

Valuation AKBLF Industry Range
Price/Earnings 100.0x
Price/Sales 3.1x
Price/Book 3.1x
Price/Cash Flow 107.6x
TEV/Sales 2.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at